Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting

被引：12

作者：

Ueno T. ^{[1
]}

Koiwaya H. ^{[2
]}

Sasaki K.-I. ^{[1
]}

Katsuki Y. ^{[3
]}

Katsuda Y. ^{[4
]}

Murasato Y. ^{[5
]}

Shimamatsu J. ^{[6
]}

Umeji K. ^{[7
]}

Otsuka Y. ^{[8
]}

Kawasaki T. ^{[7
]}

Shibata Y. ^{[2
]}

Fukumoto Y. ^{[1
]}

机构：

[1] Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume

[2] Department of Cardiology, Cardiovascular Center, Miyazaki Medical Association Hospital, Miyazaki

[3] Division of Cardiology, Sugi Hospital, Omuta

[4] Division of Cardiovascular Internal Medicine, Fukuoka City Medical Association Hospital, Fukuoka

[5] Department of Cardiology, Kyushu Medical Center, Fukuoka

[6] Division of Cardiovascular Internal Medicine, Tanushimaru Chuo Hospital, Kurume

[7] Department of Cardiology, Cardiovascular Center, Shin-Koga Hospital, Kurume

[8] Department of Cardiology, Fukuoka Wajiro Hospital, Fukuoka

来源：

Cardiovascular Intervention and Therapeutics | 2017年 / 32卷 / 4期

关键词：

Clopidogrel; Coronary stent; P2Y12 reaction unit (PRU); Prasugrel; Thienopyridine;

D O I：

10.1007/s12928-016-0417-x

中图分类号：

学科分类号：

摘要：

Patients with ischemic heart disease are administered a dual antiplatelet therapy after percutaneous coronary intervention. This consists of aspirin and thienopyridine, which can be switched from prasugrel to clopidogrel. However, the impact of switching is unknown. This study aimed to determine the efficacy and safety of switching from prasugrel to clopidogrel in Japanese patients. One-hundred and thirty-six patients with acute coronary syndrome scheduled to undergo percutaneous coronary intervention and patients with coronary artery disease requiring elective coronary stenting were enrolled. Patients were randomly assigned into the following groups: prasugrel for 6 weeks at loading/maintenance doses of 20/3.75 mg (Continued Group; n = 68) or prasugrel at 20/3.75 mg for 2 weeks followed by clopidogrel at 75 mg for 4 weeks (Switched Group; n = 68). Aspirin (loading dose/maintenance dose 324/81–100 mg/day) was coadministered in both groups. The primary endpoint was the mean P2Y12 reaction unit (PRU) at week 6 and the secondary endpoint was the PRU in groups subdivided based on the presence of CYP2C19 gene polymorphisms. At week 6, the PRU was significantly lower in the Continued Group relative to the Switched Group (140.7 and 183.0, respectively; P < 0.001), which was also evident after correction with the baseline values (144.1 vs. 176.6, respectively; P = 0.005). Extensive and poor metabolizers in the Switched Group, based on CYP2C19 gene polymorphisms, had significantly higher PRU values than those in the Continued Group. Thus, switching treatments from prasugrel to clopidogrel significantly increased the PRU in patients receiving antiplatelet therapy subsequent to percutaneous coronary intervention. Clinical Trial Registration UMIN ID, UMIN000015122. © 2016, Japanese Association of Cardiovascular Intervention and Therapeutics.

引用

页码：341 / 350

页数：9

共 23 条

[1] O'Gara P.T., Kushner F.G., Ascheim D.D., Casey D.E., Chung M.K., de Lemos J.A., Et al., ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 61, 4, pp. e78-e140, (2013)
[2] Levine G.N., Bates E.R., Blankenship J.C., Bailey S.R., Bittl J.A., Cercek B., Et al., ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions, J Am Coll Cardiol, 58, 24, pp. e44-e122, (2011)
[3] Windecker S., Kolh P., Alfonso F., Collet J.P., Cremer J., Falk V., Et al., ESC/EACTS Guidelines onmyocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), Eur Heart J, 35, pp. 2541-2619, (2014)
[4] Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease, JCS, (2009)
[5] Steinhubl S.R., Berger P.B., Mann J.T., Fry E.T., DeLago A., Wilmer C., Et al., Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial, JAMA, 288, 19, pp. 2411-2420, (2002)
[6] Furuta T., Shirai N., Sugimoto M., Nakamura A., Hishida A., Ishizaki T., Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies, Drug Metab Pharmacokinet, 20, 3, pp. 153-167, (2005)
[7] Saito S., Isshiki T., Kimura T., Ogawa H., Yokoi H., Nanto S., Et al., Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study, Circ J, 78, 7, pp. 1684-1692, (2014)
[8] Yamamoto K., Hokimoto S., Chitose T., Morita K., Ono T., Kaikita K., Et al., Impact of CYP2C19 gene polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy, J Cardiol, 57, 2, pp. 194-201, (2011)
[9] Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Et al., Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 357, 20, pp. 2001-2015, (2007)
[10] Sorich M.J., Vitry A., Ward M.B., Horowitz J.D., McKinnon R.A., Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data, J Thromb Haemost, 8, 8, pp. 1678-1684, (2010)

← 1 2 3 →